Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, California.
Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.
JAMA Otolaryngol Head Neck Surg. 2023 Nov 1;149(11):1011-1020. doi: 10.1001/jamaoto.2023.2982.
Positive margins and margin clearance are risk factors for recurrence in oral cavity squamous cell carcinoma (OCSCC), and these features are used to guide decisions regarding adjuvant radiation treatment. However, the prognostic value of intraoperative tumor bed vs resection specimen sampling is not well defined.
To determine the prognostic implications of intraoperative margin assessment methods (tumor bed vs resection specimen sampling) with recurrence among patients who undergo surgical resection for OCSCC.
DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective study of patients who had undergone surgical resection of OCSCC between January 1, 2000, and December 31, 2021, at a tertiary-level academic institution. Patients were grouped by margin assessment method (tumor bed [defect] or resection specimen sampling). Of 223 patients with OCSCC, 109 patients had localized tumors (pT1-T2, cN0), 154 had advanced tumors, and 40 were included in both cohorts. Disease recurrence after surgery was estimated by the cumulative incidence method and compared between cohorts using hazard ratios (HRs). Data analyses were performed from January 5, 2023, to April 30, 2023.
Recurrence-free survival (RFS).
The study population comprised 223 patients (mean [SD] age, 62.7 [12.0] years; 88 (39.5%) female and 200 [90.0%] White individuals) of whom 158 (70.9%) had defect-driven and 65 (29.1%) had specimen-driven margin sampling. Among the 109 patients with localized cancer, intraoperative positive margins were found in 5 of 67 (7.5%) vs 8 of 42 (19.0%) for defect- vs specimen-driven sampling, respectively. Final positive margins were 3.0% for defect- (2 of 67) and 2.4% for specimen-driven (1 of 42) margin assessment. Among the 154 patients with advanced cancer, intraoperative positive margins were found in 29 of 114 (25.4%) vs 13 of 40 (32.5%) for defect- and specimen-driven margins, respectively. Final positive margins were higher in the defect-driven group (9 of 114 [7.9%] vs 1 of 40 [2.5%]). When stratified by margin assessment method, the 3-year rates of local recurrence (9.7% vs 5.1%; HR, 1.37; 95% CI, 0.51-3.66), regional recurrence (11.0% vs 10.4%; HR, 0.85; 95% CI, 0.37-1.94), and distant recurrence (6.4% vs 5.0%; HR, 1.10; 95% CI, 0.36-3.35) were not different for defect- vs specimen-driven sampling cohorts, respectively. The 3-year rate of any recurrence was 18.9% in the defect- and 15.2% in the specimen-driven cohort (HR, 0.93; 95% CI, 0.48-1.81). There were no differences in cumulative incidence of disease recurrence when comparing defect- vs specimen-driven cases.
The findings of this retrospective cohort study indicate that margin assessment methods using either defect- or specimen-driven sampling did not demonstrate a clear association with the risk of recurrence after OCSCC resection. Specimen-driven sampling may be associated with reduced surgical margin positivity rates, which often necessitate concurrent chemotherapy with adjuvant radiation therapy.
重要性:口腔鳞状细胞癌(OCSCC)中阳性切缘和切缘清除是复发的危险因素,这些特征用于指导关于辅助放疗的决策。然而,术中肿瘤床与切除标本取样的预后价值尚不清楚。
目的:确定在接受 OCSCC 手术切除的患者中,术中切缘评估方法(肿瘤床与切除标本取样)与复发之间的相关性。
设计、地点和参与者:这是一项回顾性研究,纳入了 2000 年 1 月 1 日至 2021 年 12 月 31 日期间在一家三级学术机构接受 OCSCC 手术切除的患者。患者按切缘评估方法(肿瘤床[缺陷]或切除标本取样)分组。在 223 例 OCSCC 患者中,109 例为局限性肿瘤(pT1-T2,cN0),154 例为晚期肿瘤,40 例同时入组两组。通过累积发生率法估计手术后疾病复发,并通过危险比(HR)比较两组之间的差异。数据分析于 2023 年 1 月 5 日至 2023 年 4 月 30 日进行。
主要结局和测量:无复发生存率(RFS)。
结果:研究人群包括 223 例患者(平均[标准差]年龄,62.7[12.0]岁;88[39.5%]为女性,200[90.0%]为白人),其中 158 例(70.9%)为缺陷驱动的切缘采样,65 例(29.1%)为标本驱动的切缘采样。在 109 例局限性癌症患者中,术中阳性切缘分别在 67 例(7.5%)中的 5 例和 42 例(19.0%)中的 8 例中发现,缺陷驱动组和标本驱动组分别为 3.0%(2/67)和 2.4%(1/42)。在 154 例晚期癌症患者中,术中阳性切缘分别在 114 例(25.4%)中的 29 例和 40 例(32.5%)中的 13 例中发现,缺陷驱动组和标本驱动组分别为 9.7%(9/114)和 2.5%(1/40)。按切缘评估方法分层时,局部复发的 3 年发生率(9.7% vs 5.1%;HR,1.37;95%CI,0.51-3.66)、区域复发(11.0% vs 10.4%;HR,0.85;95%CI,0.37-1.94)和远处复发(6.4% vs 5.0%;HR,1.10;95%CI,0.36-3.35)在缺陷驱动组和标本驱动组之间无差异。缺陷组和标本组的任何复发的 3 年发生率分别为 18.9%和 15.2%(HR,0.93;95%CI,0.48-1.81)。比较缺陷组和标本组,疾病复发的累积发生率无差异。
结论和相关性:这项回顾性队列研究的结果表明,使用肿瘤床或标本驱动的切缘评估方法与 OCSCC 切除后复发的风险之间没有明确的关联。标本驱动的采样可能与降低手术切缘阳性率相关,这通常需要辅助化疗和放疗。